Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01UDS
|
|||
| Former ID |
DIB005017
|
|||
| Drug Name |
CNV-2197944
|
|||
| Synonyms |
GSK-2197944; Cav2.2 channel blocker (chronic pain), GlaxoSmithKline/Convergence Pharmaceuticals
Click to Show/Hide
|
|||
| Indication | Pain [ICD-11: MG30-MG3Z] | Phase 2 | [1] | |
| Company |
GlaxoSmithKline plc
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H20F3N3O3S
|
|||
| Canonical SMILES |
CC1CN(CCN1C(=O)C2=C(N=CC=C2)C)S(=O)(=O)C3=CC=C(C=C3)C(F)(F)F
|
|||
| InChI |
1S/C19H20F3N3O3S/c1-13-12-24(10-11-25(13)18(26)17-4-3-9-23-14(17)2)29(27,28)16-7-5-15(6-8-16)19(20,21)22/h3-9,13H,10-12H2,1-2H3/t13-/m0/s1
|
|||
| InChIKey |
BLFJGFDZMABYMY-ZDUSSCGKSA-N
|
|||
| CAS Number |
CAS 1204535-44-3
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01848730) Efficacy and Safety of CNV2197944 Versus Placebo in Patients With Post-herpetic Neuralgia. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Convergence Pharmaceuticals Ltd. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.